Zenocutuzumab

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 21:41:08 GMT 2025` Edited by `admin` on `Tue Apr 01 21:41:08 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED
Sequence Type	COMPLETE
Record UNII	AE72RB1W1X
Record Status	`Validated (UNII)`
Record Version

Download

Related Record	Type

Name

Type

Language

Zenocutuzumab

Official Name

English

MCLA-128

Preferred Name

English

ZENOCUTUZUMAB [USAN]

Common Name

English

MCLA128

Code

English

Immunoglobulin G1, bispecific, anti-(human epidermal growth factor receptors, HER2 and HER3) (humanized clone MCLA-128 ?1-chain), disulfide with humanized clone MCLA-128 light chain, dimer

Common Name

English

Zenocutuzumab [WHO-DD]

Common Name

English

Immunoglobulin G1-kappa, anti-(Homo sapiens Receptor tyrosine-protein kinase erbB-3 (Proto-oncogene-like protein c-ErbB-3, Tyrosine kinase-type cell surface receptor HER3, EC=2.7.10.1)) and anti-(Homo sapiens Receptor tyrosine-protein kinase erbB-2 (Meta

Common Name

English

MCLA-128 (IGG1 BISPECIFIC ANTIBODY WITH ENHANCED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) ACTIVITY TARGETING HER2 AND HER3 RECEPTORS.)

Common Name

English

zenocutuzumab [INN]

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

750020

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

NCI_THESAURUS

C129822

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

Code System Code Type Description

CAS

1969309-56-5

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

PRIMARY

NCI_THESAURUS

C152948

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

PRIMARY

DRUG BANK

DB15559

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

PRIMARY

USAN

HI-231

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

PRIMARY

SMS_ID

300000025314

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

PRIMARY

FDA UNII

AE72RB1W1X

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

PRIMARY

INN

10687

Created by admin on Tue Apr 01 21:41:08 GMT 2025 , Edited by admin on Tue Apr 01 21:41:08 GMT 2025

PRIMARY

From	To
1_22	1_96
1_151	1_207
1_268	1_328
1_374	1_432
2_22	2_96
2_148	2_204
2_265	2_325
2_371	2_429
1_227	3_214
1_233	2_230
1_236	2_233
2_224	4_214
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194

Glycosylation Type

MAMMALIAN, AFUCOSYLATED

Glycosylation Link Type	Site
N	1_304
N	2_301

Related Record Type Details

Zenocutuzumab-ZBCO

SUB_CONCEPT->SUBSTANCE

Amount:


					7J9Y28299R

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2

TARGET -> INHIBITOR

Comments:

IgG1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity targeting HER2 and HER3 receptors.

Amount:


					RSO83C9PIA

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3

TARGET -> INHIBITOR

Comments:

IgG1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity targeting HER2 and HER3 receptors.

Amount:

Related Record Type Details


					AE72RB1W1X

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL